The global Low Molecular Weight Heparin API market size is predicted to grow from US$ 848 million in 2025 to US$ 1735 million in 2031; it is expected to grow at a CAGR of 12.7% from 2025 to 2031.
Heparin is an anticoagulant (blood thinner) that prevents the formation of blood clots. Heparin is used to treat and prevent blood clots in the veins, arteries, or lung. It is also used before surgery to reduce the risk of blood clots. Most of the Heparin product is existed in a form of Heparin Sodium or Heparin Calcium. In this report, we mainly study the low molecular weight heparin API.
The Low Molecular Weight Heparin (LMWH) API market plays a crucial role in the global pharmaceutical industry due to the widespread use of LMWHs in the prevention and treatment of blood clot-related disorders, such as deep vein thrombosis (DVT) and pulmonary embolism (PE). LMWH APIs are preferred in clinical settings for their favorable pharmacological properties, including better bioavailability, longer half-life, and reduced risk of side effects compared to unfractionated heparin. The increasing prevalence of cardiovascular diseases and venous thromboembolism, aging populations, and a rise in surgical procedures worldwide have significantly driven demand for LMWH-based therapies.
The global market for Low Molecular Weight Heparin API was estimated to be worth US$ 0.78 billion in 2024 and is forecast to a readjusted size of US$ 1.56 billion by 2030 with a CAGR of 12.21% during the forecast period 2024-2030.
The North American and European markets lead in demand due to a high prevalence of thrombosis-related conditions and advanced healthcare infrastructure. Asia-Pacific is emerging as a growth market, driven by increased healthcare spending and the rise of generics. North American market for Low Molecular Weight Heparin API was valued at $ 294.19 million in 2023 and will reach $ 523.34 million by 2030, at a CAGR of 12.54% during the forecast period of 2024 through 2030. Asia-Pacific market for Low Molecular Weight Heparin API was valued at $ 293.62 million in 2023 and will reach $ 496.95 million by 2030, at a CAGR of 12.81% during the forecast period of 2024 through 2030. Europe market for Low Molecular Weight Heparin API was valued at $ 307.93 million in 2023 and will reach $ 521.29 million by 2030, at a CAGR of 11.45% during the forecast period of 2024 through 2030.
Low Molecular Weight Heparin API segment market, the Enoxaparin Sodium holds an important share, and it is expected to reach a value of US$ 1,258.82 million by 2030, at a CAGR of 12.46% during 2024 and 2030.
The global key companies of Low Molecular Weight Heparin API include Yantai Dongcheng Pharmaceutical, Shenzhen Hepalink Pharmaceutical, Nanjing King-friend Biochemical Pharmaceutical, Changzhou Qianhong Biopharma, and Qingdao Jiulong Biopharmaceutical, etc. In 2023, the global five largest players hold a share approximately 72.91% in terms of revenue.
The 鈥淟ow Molecular Weight Heparin API Industry Forecast鈥� looks at past sales and reviews total world Low Molecular Weight Heparin API sales in 2024, providing a comprehensive analysis by region and market sector of projected Low Molecular Weight Heparin API sales for 2025 through 2031. With Low Molecular Weight Heparin API sales broken down by region, market sector and sub-sector, this report provides a detailed analysis in US$ millions of the world Low Molecular Weight Heparin API industry.
This Insight Report provides a comprehensive analysis of the global Low Molecular Weight Heparin API landscape and highlights key trends related to product segmentation, company formation, revenue, and market share, latest development, and M&A activity. This report also analyzes the strategies of leading global companies with a focus on Low Molecular Weight Heparin API portfolios and capabilities, market entry strategies, market positions, and geographic footprints, to better understand these firms鈥� unique position in an accelerating global Low Molecular Weight Heparin API market.
This Insight Report evaluates the key market trends, drivers, and affecting factors shaping the global outlook for Low Molecular Weight Heparin API and breaks down the forecast by Type, by Application, geography, and market size to highlight emerging pockets of opportunity. With a transparent methodology based on hundreds of bottom-up qualitative and quantitative market inputs, this study forecast offers a highly nuanced view of the current state and future trajectory in the global Low Molecular Weight Heparin API.
This report presents a comprehensive overview, market shares, and growth opportunities of Low Molecular Weight Heparin API market by product type, application, key manufacturers and key regions and countries.
Segmentation by Type:
Low Molecular Weight Heparin Sodium
Low Molecular Weight Heparin Calcium
Segmentation by Application:
Enoxaparin Sodium
Nadroparin Calcium
Dalteparin Sodium
Tinzaparin Sodium
Parnaparin Sodium
This report also splits the market by region:
Americas
United States
Canada
Mexico
Brazil
APAC
China
Japan
Korea
Southeast Asia
India
Australia
Europe
Germany
France
UK
Italy
Russia
Middle East & Africa
Egypt
South Africa
Israel
Turkey
GCC Countries
The below companies that are profiled have been selected based on inputs gathered from primary experts and analysing the company's coverage, product portfolio, its market penetration.
Yantai Dongcheng Pharmaceutical
Shenzhen Hepalink Pharmaceutical
Nanjing King-friend
Changzhou Qianhong Biopharma
Qingdao Jiulong Biopharmaceutical
Dongying Tiandong Pharmaceutical
Yino Pharma
Opocrin
Hebei Changshan
Hubei Enoray Biopharmaceutical
Nanjing Nanda Pharmaceutical
Cisen Pharmaceutical
Key Questions Addressed in this Report
What is the 10-year outlook for the global Low Molecular Weight Heparin API market?
What factors are driving Low Molecular Weight Heparin API market growth, globally and by region?
Which technologies are poised for the fastest growth by market and region?
How do Low Molecular Weight Heparin API market opportunities vary by end market size?
How does Low Molecular Weight Heparin API break out by Type, by Application?
Please Note - This is an on demand report and will be delivered in 2 business days (48 hours) post payment.
1 Scope of the Report
1.1 Market Introduction
1.2 Years Considered
1.3 Research Objectives
1.4 Market Research Methodology
1.5 Research Process and Data Source
1.6 Economic Indicators
1.7 Currency Considered
1.8 Market Estimation Caveats
2 Executive Summary
2.1 World Market Overview
2.1.1 Global Low Molecular Weight Heparin API Annual Sales 2020-2031
2.1.2 World Current & Future Analysis for Low Molecular Weight Heparin API by Geographic Region, 2020, 2024 & 2031
2.1.3 World Current & Future Analysis for Low Molecular Weight Heparin API by Country/Region, 2020, 2024 & 2031
2.2 Low Molecular Weight Heparin API Segment by Type
2.2.1 Low Molecular Weight Heparin Sodium
2.2.2 Low Molecular Weight Heparin Calcium
2.3 Low Molecular Weight Heparin API Sales by Type
2.3.1 Global Low Molecular Weight Heparin API Sales Market Share by Type (2020-2025)
2.3.2 Global Low Molecular Weight Heparin API Revenue and Market Share by Type (2020-2025)
2.3.3 Global Low Molecular Weight Heparin API Sale Price by Type (2020-2025)
2.4 Low Molecular Weight Heparin API Segment by Application
2.4.1 Enoxaparin Sodium
2.4.2 Nadroparin Calcium
2.4.3 Dalteparin Sodium
2.4.4 Tinzaparin Sodium
2.4.5 Parnaparin Sodium
2.5 Low Molecular Weight Heparin API Sales by Application
2.5.1 Global Low Molecular Weight Heparin API Sale Market Share by Application (2020-2025)
2.5.2 Global Low Molecular Weight Heparin API Revenue and Market Share by Application (2020-2025)
2.5.3 Global Low Molecular Weight Heparin API Sale Price by Application (2020-2025)
3 Global by Company
3.1 Global Low Molecular Weight Heparin API Breakdown Data by Company
3.1.1 Global Low Molecular Weight Heparin API Annual Sales by Company (2020-2025)
3.1.2 Global Low Molecular Weight Heparin API Sales Market Share by Company (2020-2025)
3.2 Global Low Molecular Weight Heparin API Annual Revenue by Company (2020-2025)
3.2.1 Global Low Molecular Weight Heparin API Revenue by Company (2020-2025)
3.2.2 Global Low Molecular Weight Heparin API Revenue Market Share by Company (2020-2025)
3.3 Global Low Molecular Weight Heparin API Sale Price by Company
3.4 Key Manufacturers Low Molecular Weight Heparin API Producing Area Distribution, Sales Area, Product Type
3.4.1 Key Manufacturers Low Molecular Weight Heparin API Product Location Distribution
3.4.2 Players Low Molecular Weight Heparin API Products Offered
3.5 Market Concentration Rate Analysis
3.5.1 Competition Landscape Analysis
3.5.2 Concentration Ratio (CR3, CR5 and CR10) & (2023-2025)
3.6 New Products and Potential Entrants
3.7 Market M&A Activity & Strategy
4 World Historic Review for Low Molecular Weight Heparin API by Geographic Region
4.1 World Historic Low Molecular Weight Heparin API Market Size by Geographic Region (2020-2025)
4.1.1 Global Low Molecular Weight Heparin API Annual Sales by Geographic Region (2020-2025)
4.1.2 Global Low Molecular Weight Heparin API Annual Revenue by Geographic Region (2020-2025)
4.2 World Historic Low Molecular Weight Heparin API Market Size by Country/Region (2020-2025)
4.2.1 Global Low Molecular Weight Heparin API Annual Sales by Country/Region (2020-2025)
4.2.2 Global Low Molecular Weight Heparin API Annual Revenue by Country/Region (2020-2025)
4.3 Americas Low Molecular Weight Heparin API Sales Growth
4.4 APAC Low Molecular Weight Heparin API Sales Growth
4.5 Europe Low Molecular Weight Heparin API Sales Growth
4.6 Middle East & Africa Low Molecular Weight Heparin API Sales Growth
5 Americas
5.1 Americas Low Molecular Weight Heparin API Sales by Country
5.1.1 Americas Low Molecular Weight Heparin API Sales by Country (2020-2025)
5.1.2 Americas Low Molecular Weight Heparin API Revenue by Country (2020-2025)
5.2 Americas Low Molecular Weight Heparin API Sales by Type (2020-2025)
5.3 Americas Low Molecular Weight Heparin API Sales by Application (2020-2025)
5.4 United States
5.5 Canada
5.6 Mexico
5.7 Brazil
6 APAC
6.1 APAC Low Molecular Weight Heparin API Sales by Region
6.1.1 APAC Low Molecular Weight Heparin API Sales by Region (2020-2025)
6.1.2 APAC Low Molecular Weight Heparin API Revenue by Region (2020-2025)
6.2 APAC Low Molecular Weight Heparin API Sales by Type (2020-2025)
6.3 APAC Low Molecular Weight Heparin API Sales by Application (2020-2025)
6.4 China
6.5 Japan
6.6 South Korea
6.7 Southeast Asia
6.8 India
6.9 Australia
6.10 China Taiwan
7 Europe
7.1 Europe Low Molecular Weight Heparin API by Country
7.1.1 Europe Low Molecular Weight Heparin API Sales by Country (2020-2025)
7.1.2 Europe Low Molecular Weight Heparin API Revenue by Country (2020-2025)
7.2 Europe Low Molecular Weight Heparin API Sales by Type (2020-2025)
7.3 Europe Low Molecular Weight Heparin API Sales by Application (2020-2025)
7.4 Germany
7.5 France
7.6 UK
7.7 Italy
7.8 Russia
8 Middle East & Africa
8.1 Middle East & Africa Low Molecular Weight Heparin API by Country
8.1.1 Middle East & Africa Low Molecular Weight Heparin API Sales by Country (2020-2025)
8.1.2 Middle East & Africa Low Molecular Weight Heparin API Revenue by Country (2020-2025)
8.2 Middle East & Africa Low Molecular Weight Heparin API Sales by Type (2020-2025)
8.3 Middle East & Africa Low Molecular Weight Heparin API Sales by Application (2020-2025)
8.4 Egypt
8.5 South Africa
8.6 Israel
8.7 Turkey
8.8 GCC Countries
9 Market Drivers, Challenges and Trends
9.1 Market Drivers & Growth Opportunities
9.2 Market Challenges & Risks
9.3 Industry Trends
10 Manufacturing Cost Structure Analysis
10.1 Raw Material and Suppliers
10.2 Manufacturing Cost Structure Analysis of Low Molecular Weight Heparin API
10.3 Manufacturing Process Analysis of Low Molecular Weight Heparin API
10.4 Industry Chain Structure of Low Molecular Weight Heparin API
11 Marketing, Distributors and Customer
11.1 Sales Channel
11.1.1 Direct Channels
11.1.2 Indirect Channels
11.2 Low Molecular Weight Heparin API Distributors
11.3 Low Molecular Weight Heparin API Customer
12 World Forecast Review for Low Molecular Weight Heparin API by Geographic Region
12.1 Global Low Molecular Weight Heparin API Market Size Forecast by Region
12.1.1 Global Low Molecular Weight Heparin API Forecast by Region (2026-2031)
12.1.2 Global Low Molecular Weight Heparin API Annual Revenue Forecast by Region (2026-2031)
12.2 Americas Forecast by Country (2026-2031)
12.3 APAC Forecast by Region (2026-2031)
12.4 Europe Forecast by Country (2026-2031)
12.5 Middle East & Africa Forecast by Country (2026-2031)
12.6 Global Low Molecular Weight Heparin API Forecast by Type (2026-2031)
12.7 Global Low Molecular Weight Heparin API Forecast by Application (2026-2031)
13 Key Players Analysis
13.1 Yantai Dongcheng Pharmaceutical
13.1.1 Yantai Dongcheng Pharmaceutical Company Information
13.1.2 Yantai Dongcheng Pharmaceutical Low Molecular Weight Heparin API Product Portfolios and Specifications
13.1.3 Yantai Dongcheng Pharmaceutical Low Molecular Weight Heparin API Sales, Revenue, Price and Gross Margin (2020-2025)
13.1.4 Yantai Dongcheng Pharmaceutical Main Business Overview
13.1.5 Yantai Dongcheng Pharmaceutical Latest Developments
13.2 Shenzhen Hepalink Pharmaceutical
13.2.1 Shenzhen Hepalink Pharmaceutical Company Information
13.2.2 Shenzhen Hepalink Pharmaceutical Low Molecular Weight Heparin API Product Portfolios and Specifications
13.2.3 Shenzhen Hepalink Pharmaceutical Low Molecular Weight Heparin API Sales, Revenue, Price and Gross Margin (2020-2025)
13.2.4 Shenzhen Hepalink Pharmaceutical Main Business Overview
13.2.5 Shenzhen Hepalink Pharmaceutical Latest Developments
13.3 Nanjing King-friend
13.3.1 Nanjing King-friend Company Information
13.3.2 Nanjing King-friend Low Molecular Weight Heparin API Product Portfolios and Specifications
13.3.3 Nanjing King-friend Low Molecular Weight Heparin API Sales, Revenue, Price and Gross Margin (2020-2025)
13.3.4 Nanjing King-friend Main Business Overview
13.3.5 Nanjing King-friend Latest Developments
13.4 Changzhou Qianhong Biopharma
13.4.1 Changzhou Qianhong Biopharma Company Information
13.4.2 Changzhou Qianhong Biopharma Low Molecular Weight Heparin API Product Portfolios and Specifications
13.4.3 Changzhou Qianhong Biopharma Low Molecular Weight Heparin API Sales, Revenue, Price and Gross Margin (2020-2025)
13.4.4 Changzhou Qianhong Biopharma Main Business Overview
13.4.5 Changzhou Qianhong Biopharma Latest Developments
13.5 Qingdao Jiulong Biopharmaceutical
13.5.1 Qingdao Jiulong Biopharmaceutical Company Information
13.5.2 Qingdao Jiulong Biopharmaceutical Low Molecular Weight Heparin API Product Portfolios and Specifications
13.5.3 Qingdao Jiulong Biopharmaceutical Low Molecular Weight Heparin API Sales, Revenue, Price and Gross Margin (2020-2025)
13.5.4 Qingdao Jiulong Biopharmaceutical Main Business Overview
13.5.5 Qingdao Jiulong Biopharmaceutical Latest Developments
13.6 Dongying Tiandong Pharmaceutical
13.6.1 Dongying Tiandong Pharmaceutical Company Information
13.6.2 Dongying Tiandong Pharmaceutical Low Molecular Weight Heparin API Product Portfolios and Specifications
13.6.3 Dongying Tiandong Pharmaceutical Low Molecular Weight Heparin API Sales, Revenue, Price and Gross Margin (2020-2025)
13.6.4 Dongying Tiandong Pharmaceutical Main Business Overview
13.6.5 Dongying Tiandong Pharmaceutical Latest Developments
13.7 Yino Pharma
13.7.1 Yino Pharma Company Information
13.7.2 Yino Pharma Low Molecular Weight Heparin API Product Portfolios and Specifications
13.7.3 Yino Pharma Low Molecular Weight Heparin API Sales, Revenue, Price and Gross Margin (2020-2025)
13.7.4 Yino Pharma Main Business Overview
13.7.5 Yino Pharma Latest Developments
13.8 Opocrin
13.8.1 Opocrin Company Information
13.8.2 Opocrin Low Molecular Weight Heparin API Product Portfolios and Specifications
13.8.3 Opocrin Low Molecular Weight Heparin API Sales, Revenue, Price and Gross Margin (2020-2025)
13.8.4 Opocrin Main Business Overview
13.8.5 Opocrin Latest Developments
13.9 Hebei Changshan
13.9.1 Hebei Changshan Company Information
13.9.2 Hebei Changshan Low Molecular Weight Heparin API Product Portfolios and Specifications
13.9.3 Hebei Changshan Low Molecular Weight Heparin API Sales, Revenue, Price and Gross Margin (2020-2025)
13.9.4 Hebei Changshan Main Business Overview
13.9.5 Hebei Changshan Latest Developments
13.10 Hubei Enoray Biopharmaceutical
13.10.1 Hubei Enoray Biopharmaceutical Company Information
13.10.2 Hubei Enoray Biopharmaceutical Low Molecular Weight Heparin API Product Portfolios and Specifications
13.10.3 Hubei Enoray Biopharmaceutical Low Molecular Weight Heparin API Sales, Revenue, Price and Gross Margin (2020-2025)
13.10.4 Hubei Enoray Biopharmaceutical Main Business Overview
13.10.5 Hubei Enoray Biopharmaceutical Latest Developments
13.11 Nanjing Nanda Pharmaceutical
13.11.1 Nanjing Nanda Pharmaceutical Company Information
13.11.2 Nanjing Nanda Pharmaceutical Low Molecular Weight Heparin API Product Portfolios and Specifications
13.11.3 Nanjing Nanda Pharmaceutical Low Molecular Weight Heparin API Sales, Revenue, Price and Gross Margin (2020-2025)
13.11.4 Nanjing Nanda Pharmaceutical Main Business Overview
13.11.5 Nanjing Nanda Pharmaceutical Latest Developments
13.12 Cisen Pharmaceutical
13.12.1 Cisen Pharmaceutical Company Information
13.12.2 Cisen Pharmaceutical Low Molecular Weight Heparin API Product Portfolios and Specifications
13.12.3 Cisen Pharmaceutical Low Molecular Weight Heparin API Sales, Revenue, Price and Gross Margin (2020-2025)
13.12.4 Cisen Pharmaceutical Main Business Overview
13.12.5 Cisen Pharmaceutical Latest Developments
14 Research Findings and Conclusion
听
听
*If Applicable.
